A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

[1]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Renato Martins,et al.  Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines , 2013 .

[3]  F. Rödel,et al.  Frontiers Research Topic: Radiation-Induced Effects and the Immune System , 2013, Front. Oncol..

[4]  A. Chang,et al.  Effects of Tumor Irradiation on Host T-Regulatory Cells and Systemic Immunity in the Context of Adoptive T-Cell Therapy in Mice , 2013, Journal of immunotherapy.

[5]  R. G. van der Most,et al.  Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies , 2012, British Journal of Cancer.

[6]  J. Hodge,et al.  Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. , 2012, Cancer biotherapy & radiopharmaceuticals.

[7]  M. de Perrot,et al.  Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T-Cell Depletion in a Murine Mesothelioma Model , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Xiang Huang,et al.  Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. , 2011, World journal of gastroenterology.

[9]  J. Higgins,et al.  Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses , 2011, Cancer Immunology, Immunotherapy.

[10]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[11]  L. Zitvogel,et al.  Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway , 2010, Clinical Cancer Research.

[12]  Jun Shi,et al.  The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy , 2010, Cancer Immunology, Immunotherapy.

[13]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[14]  Y. Soon,et al.  Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Senzer,et al.  Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients , 2009, Cancer Gene Therapy.

[16]  M. Gyulai,et al.  Platinum-Based Chemotherapy in Lung Cancer Affects the Expression of Certain Biomarkers Including ERCC1 , 2009, Pathology & Oncology Research.

[17]  N. Senzer,et al.  Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Galetta,et al.  Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). , 2008, Lung cancer.

[19]  A. de la Torre,et al.  Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  D. Mavroudis,et al.  Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Nelson,et al.  Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells , 2007, Cell biology international.

[23]  J. Mantil,et al.  Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma , 2006, Cancer Gene Therapy.

[24]  N. Senzer,et al.  Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[26]  P. Ellis,et al.  Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Stewart.  Update on the role of topotecan in the treatment of non-small cell lung cancer. , 2004, The oncologist.

[28]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Schlesselman,et al.  Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Hirschowitz,et al.  Autologous dendritic cell vaccines for non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Fox,et al.  Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.

[32]  Michael J Schell,et al.  Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Dogliotti,et al.  Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. , 1996, Lung cancer.

[34]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[35]  M. Socinski,et al.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[36]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[37]  Leslie H. Sobin,et al.  TNM Classification of Malignant Tumours, 7th Edition , 2009 .